IOVA Iovance Biotherapeutics Inc: Multiplikator nilai perusahaan marang pendapatan

Logo perusahaan publik iovance.com (IOVA)

Scaling the network of medical centers reduces the production costs of personalized medicines, creating strong operating leverage for Iovance Biotherapeutics (IOVA). The EV/Sales multiple reflects the current market valuation, with the latest mark standing at 8051.57. While its leadership status in T-cell therapy earns Iovance Biotherapeutics (IOVA) the trust of physicians, fierce competition with biotech behemoths and the risk of cheaper generics pose significant challenges for the business.

Nilai perusahaan marang pendapatan: Iovance Biotherapeutics Inc (IOVA) kanggo 23.11.2025 - 20.11.2026

iovance.com - rincian analitis lan metrik utama (IOVA)

- rega saham lan konsensus proyeksi valuasi:
Analisis wiwitan perusahaan:Iovance Biotherapeutics IOVA
Sampel barang Iovance Biotherapeutics

For Iovance Biotherapeutics (IOVA), the expansion of clean room capacities directly impacts future revenue, making the EV/Sales analysis critically important. This metric compares the enterprise value of the business, including net debt, against annual sales volume. Analyzing the business valuation via EV/Sales allows for the determination of whether the asset is overbought relative to its historical trend. It is vital for investors to avoid entering at the peak of the valuation cycle. Effective re-equipping of production lines should lead to an organic decrease in this ratio.

Analisis pesaing Iovance Biotherapeutics

IBRX (immunitybio.com) - Rasio nilai perusahaan marang pendapatan|Immunocore Corp (IMCR) - Rasio nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Janux Pharma (JANX)|Nilai perusahaan marang pendapatan RCUS|ZYME - Rasio nilai perusahaan marang dodolan|Nilai perusahaan marang pendapatan TNGX (Tango Pharma)|Koefisien nilai perusahaan marang pendapatan IMTX|Multiplikator EV/Sales XNCR (Xencor)|Nilai bisnis marang pendapatan CMPX|replimune.com - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Lyell Pharma|Innate Pharma S.A. (IPHA) - Rasio nilai perusahaan marang pendapatan|Pyxis Oncology Inc. - Nilai bisnis marang pendapatan|CGEN (Compugen Limited) - Multiplikator EV/Sales|Multiplikator EV/Sales IO Biotech Inc|Rasio nilai perusahaan marang pendapatan Sutro Biopharma (STRO)|INKT: Nilai perusahaan marang volume dodolan|Werewolf Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Immix (IMMX) - Multiplikator nilai perusahaan marang pendapatan|ALX Oncology Holdings Inc. - Multiplikator EV/Sales|CUE - Multiplikator EV/Sales|PDSB: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan Liminatus Pharma (LIMN)|Multiplikator EV/Sales LVTX|Koefisien nilai perusahaan marang pendapatan NXTC|Leap Therapeutics, Inc. - Nilai perusahaan marang pendapatan|INTS: Rasio nilai perusahaan marang pendapatan|Sensei Biotherapeutics Inc - Multiplikator EV/Sales|TOVX: Rasio nilai perusahaan marang pendapatan|gritstonebio.com (GRTS) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan KA|Rasio nilai perusahaan marang pendapatan NexImmune, Inc.|Rasio nilai perusahaan marang pendapatan TSBX (Turnstone Biologics)|Nilai perusahaan marang pendapatan VCNX (Vaccinex, Inc.)|Koefisien nilai perusahaan marang pendapatan HARP